Fig. 1From: Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patientsProgression-free survival (Panel A) and overall survival (Panel B) of the original cohort; Progression-free survival (Panel C) and overall survival (Panel D) of the propensity-score matching cohort. Abbreviations: HR = hazard ratio; CI = confidence intervalBack to article page